Why Biosimilars are changing the Pharmaceutical Industry
The pharmaceutical industry shifts due to biosimilars because these products extend medical treatment access to crucial therapeutics and minimize healthcare expenses through affordable versions of high-cost biologics. The pharmaceutical industry experiences fundamental changes because U.S. Biosimilars secure multiple regulatory approvals for exact versions of approved biologic drugs which lowers healthcare expenditures globally through their inexpensive…
divyaochre
Contract Manufacturing in Biopharma Evolving Beyond COVID-19
The COVID-19 pandemic catalyzed changes to the biopharma manufacturing landscape, with agility, innovation, and resilience becoming necessary prerequisites. And digital transformation, single-use technologies, and strategic partnerships were driving contract manufacturing that soared. Demand is rebounding, but regulatory changes and automation are reshaping the industry. Welcome to the future, where the nature of demand is shifting,…
Data-Enriched Edible Pharmaceuticals (DEEP)
Data-Enriched Edible Pharmaceuticals (DEEP) as Patient-Tailored Drug Products AUTHORS: Natalja Genina, Associate Professor, University of Copenhagen (UCPH) Jukka Rantanen, Professor, UCPH Johan Bøtker, Associate Professor, UCPH Sofia Kalvemark Sporrong, Professor, Uppsala University Data-enriched edible pharmaceuticals (DEEP) is a novel pharmaceutical product design principle. DEEP has been proposed as a solution for personalized medicines, where each drug product, i.e., ‘every…
Optimizing Portfolio Management in Pharma CDMOs Strategies
Optimizing Portfolio Management in Pharma CDMOs: Strategies for Sustainable Growth Author: Deepak Khurana, CPSCM™ is a Vice President Procurement & SCM, Suven Pharmaceuticals In the competitive and regulated pharmaceutical industry, effective portfolio management is critical for contract development and manufacturing organizations (CDMOs) aiming for sustained growth and long-term success. This article explores strategies to optimize…
How AI is Transforming the Pharmaceutical Industry
Authors: Chandramouli Ramnarayanan, PhD, Global Technical Enablement Engineer, JMP Statistical Discovery LLC Dr. Valliappan Kannappan, Founder, Chiralpedia Artificial Intelligence (AI) is revolutionizing Europe’s pharmaceutical landscape by accelerating drug discovery, streamlining clinical trials, and enhancing personalized patient care. Innovations from companies like Exscientia and Healx significantly shorten development timelines, while regulators grapple with balancing rapid innovation against ethical…
Nano-Carrier based Smart Drug Delivery Systems
Nano-Carrier based Smart Drug Delivery Systems: Taking Aim at Cancer Therapy Sidharth Mehta, Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and & Technology Nikita Yadav, Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science & Technology The creation of smart nanocarrier-based drug delivery systems, also known as Smart Drug Delivery Systems(SDDSs), was prompted by the…
Unlocking the Power of Biomarkers: A Comprehensive Guide
Biomarkers, spanning genes, proteins, and imaging features, are pivotal in healthcare, offering insights into disease, personalized treatment, and drug development. Challenges include standardization and ethical considerations. The future lies in multiomics, integrating genomics, proteomics, and more, facilitated by technology and machine learning. Liquid biopsy emerges as a non-invasive tool. Embracing this biomarker revolution promises a…
Revolutionizing Healthcare: Gene Editing for Genetic Disorde
CRISPR technology, with its precision in gene editing, revolutionizes healthcare by enabling personalized treatments for genetic disorders. It’s potential for correcting mutations, therapeutic applications, in vivo gene editing, and early intervention holds promise for transformative solutions. However, ethical considerations and ongoing research are crucial for responsible implementation and unlocking the full potential of CRISPR in…
New PostAlpha-fetoprotein as a Shuttle for Medicines
Author: Vladimir N Pak, freelance researcher Alpha-fetoprotein (AFP) delivers ligands to monocytes/macrophages that regulate the immune system activity. AFP or AFP-drugs can be used to treat autoimmune diseases, while AFP-toxin can treat cancer. Injectable and oral AFP-toxin formulations demonstrated anticancer activity. Pregnancy is a natural phenomenon that ensures the survival of the species. The suppression…